|
 |
AzactamThis page contains recent news articles, when available, and an overview of Azactam but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The "aztreonam" part of aztreonam lysine is the active ingredient in Elan's (NYSE: ELN) injected antibiotic Azactam, which was originally developed by ... Motley Fool Elan Swings To Profit In Q3 - Oct 21, 2009 Azactam revenue fell 18% to $19.8 million from $24.2 million in 2008, primarily due to supply shortages, while Maxipime revenue plunged 68% to $1.8 million ... RTT News Elan Corporation, plc - SWOT Analysis - Oct 23, 2009 Other marketed products in its portfolio include Prialt, Maxipime and Azactam. Elan is headquartered in Dublin, Ireland and employed 1610 people as of ... PRMinds (press release) REG-Elan Corporation PLC Elan Reports Third Quarter 2009 Financial Results - Oct 21, 2009 The increase in revenue from the Biopharmaceuticals business was driven by a solid performance from Tysabri®, more than offsetting reduced sales of Azactam® ... Reuters Elan Reports Third Quarter 2009 Financial Results - Oct 22, 2009 ...from the Biopharmaceuticals business was driven by a solid performance from Tysabri ® , more than offsetting reduced sales of Azactam ® and Maxipime ® . ... Business Wire (press release) Elan 虧æ??å°?æ–¼é ?期 - Oct 21, 2009 ...生物製藥收入æˆ?é•·ï¼Œæ˜¯å› Tysabri銷售æˆ?長，抵銷Azactam與Maxipime銷售的下跌。 Elançš„Tysabri銷售é¡?å¢žåŠ 16%，創新高é?”1.914憶美元，2008年第三å£ç‚º1.645憶美元。 ... 環球財經 |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |